Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere - Fierce Biotech
Source: Fierce Biotech ·
Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere Fierce BiotechGenmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer Business WireGenmab’s Rina-S shows durable responses in ovarian cancer The Pharma LetterWeekly Recap: Rina‑S 45.9%…